Innovent's Eye Drug Just Matched the King of Retinas

For context, standard Eylea dosing runs every eight weeks after the loading phase. And Roche's Vabysmo (faricimab), which launched as a next-gen competitor with extended dosing as its selling point, only got about 45% of patients to 16-week intervals in comparable trials. Innovent's drug didn't just match Eylea on efficacy; it potentially beat both Eylea and Vabysmo on convenience.

In a disease that requires lifelong treatment, fewer injections isn't a luxury. It's a game-changer for patient compliance and quality of life. It's the difference between a subscription you tolerate and one you can actually live with.

A Safer Pair of Hands?

There's a growing concern in retinal medicine that long-term anti-VEGF treatment can cause macular atrophy, a thinning of the retina that can itself threaten vision. It's an ironic side effect: you treat the disease, but the treatment slowly damages the very tissue you're trying to save.

Efdamrofusp alfa posted a macular atrophy rate of 1.5%, compared to 2.9% for Eylea. That's roughly half the rate. Innovent believes the complement-targeting component of the drug may be protective, essentially shielding the retina from the kind of inflammatory damage that other anti-VEGF therapies can cause over time.

One trial doesn't settle the debate, and longer-term data will be critical. But if that safety signal holds up, it gives Innovent a compelling story to tell regulators and doctors alike.

Why China Is the Prize

Innovent isn't chasing FDA approval (at least not yet). The company is focused on winning in China, and there's good reason for that.

China's ophthalmic drug market is large and growing rapidly. The patient population is enormous: China has one of the world's highest rates of diabetes (which causes diabetic retinopathy) and a rapidly aging population vulnerable to wet AMD.

Meanwhile, Eylea's grip on China is loosening. The drug's growth in the region has plateaued or even started declining amid intensified competition and biosimilar pressure. Regeneron's global Eylea sales already took a hit in late 2025, with the combined U.S. EYLEA and EYLEA HD franchise's Q4 revenue dropping 28% year-over-year.

Innovent doesn't need to dethrone Eylea worldwide. It just needs to capture meaningful share in a market that's growing fast and where the incumbent is vulnerable. A locally developed drug with non-inferior efficacy, better dosing convenience, and a potentially cleaner safety profile? That's a strong pitch to Chinese physicians and regulators.

The Bigger Ophthalmology Play

Efdamrofusp alfa isn't Innovent's only card. The company also has IBI324, a bispecific antibody targeting both VEGF and Ang2 (another protein involved in blood vessel leakage). In a Phase 1b trial reported in January 2026, IBI324 showed superior anatomic outcomes compared to Vabysmo in both diabetic macular edema and wet AMD, with equivalent vision gains and no intraocular inflammation.

Phase 3 trials for IBI324 are planned but haven't started yet. If both candidates advance, Innovent would have a genuine ophthalmology franchise: one drug for the established market, another potentially leapfrogging the next-gen competition.

The company also has IBI333, a bispecific fusion protein targeting VEGF-A and VEGF-C, currently in Phase 1 for wet AMD. It's early, but the pipeline shows Innovent isn't making a one-off bet. They're building an eye care portfolio.

The Bottom Line

Matching Eylea in a Phase 3 trial is the table stakes. What makes Innovent's story worth watching is everything around those results: the dosing advantage, the safety signal, the timing in a China market that's ripe for a local challenger, and a pipeline that suggests this is act one, not the whole show.

The path to China approval (via the NMPA) still lies ahead, and we don't yet have a confirmed filing timeline. Longer-term data on macular atrophy will either cement or undermine the safety narrative. And competing in a market where Eylea and Vabysmo have established relationships with physicians won't be easy, even on home turf.

But if you're looking for a biotech ophthalmology story that combines strong clinical data with a clear commercial thesis, Innovent just put one on the board. The king of retinas has a new challenger, and this one speaks Mandarin.

The Party Balloon Gas That Could Shut Down Hospital MRIs

Iranian strikes knocked out a third of the world's helium supply, and 50,000 MRI scanners are about to feel it. The crisis linking party balloons to cancer screenings is more urgent than you think.